RE:RE:RE:RE:SP off 30%+ since Seto became CEODomino55 wrote: MM-Have you seen any signs of a possible mandate change to date? I don't.
The Share Price still seems to flap in the wind untethered to the clinical milestones they continue to hit.
Nope.
It still seems to be that "mums the word" ...despite lots of good things that could be embellished highlighted, summarized, disseminated, etc. Info. that the market would likely eat up, while at the same time it might very well help to create demand for shares and therefor would be supportive of share price, and value discovery ...especially if the the right markets were included and brought up to speed.
Other advantages of being less mum?
- hope for future patients or at risk individuals
- hope for ICU profesionals (that need more tools to combat a leading killer)
- lower cost of capital going forward (using share price as currency)
- faster uptick once commercilization phase is reached (advance education)
- less dilution experienced by existing shareholders on future raises
example...how about a NR summarizing the high points of yesterday's sessions in Europa?
LIVE SESSION
Thursday MAY 27
17.15-18.30 CEST – Live Hall 1
THE MANY FACES OF ENDOTOXIC SHOCK: ROLE OF POLYMYXIN B HEMOPERFUSION
Chairpersons: M. Antonelli (Roma) and R. Ferrer Roca (Barcelona)
Superinfections and endotoxemia in septic and COVID-19 patients
R. Ferrer Roca (Barcelona)
Endotoxic shock and Polymyxin B hemoperfusion in pulmonary and COVID-19 patients
C. Ronco (Vicenza)